Lilly Building On Gemzar Through Sanofi Oxaliplatin Joint Venture

Lilly plans to build its presence in the U.S. oncology market by adding Sanofi's colorectal cancer agent oxaliplatin to the pancreatic cancer therapy Gemzar (gemcitabine) under a joint venture agreement announced April 19.